{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:05:06Z","timestamp":1791515106544,"version":"4.3.4"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002370"],"award-info":[{"award-number":["KL2TR002370"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA262496"],"award-info":[{"award-number":["R01CA262496"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA28459"],"award-info":[{"award-number":["R01CA28459"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA283574"],"award-info":[{"award-number":["R01CA283574"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The World Health Organization fifth edition and International Consensus Classification for myeloid neoplasms both incorporate empirical numerical thresholds to morphologic and molecular features defining certain disease entities. However, the clinical implications of these thresholds remain unclear. We analyzed a large cohort (N = 6,976) of patients with myeloid neoplasms to evaluate the impact of proposed yet different numerical thresholds for variant allele frequency of genetic mutations or hematologic parameters set forth by the World Health Organization fifth edition and International Consensus Classification for classification of SF3B1-mutated myelodysplastic neoplasms, NPM1-mutated acute myeloid leukemia (AML), and oligomonocytic chronic myelomonocytic leukemia. Our analysis demonstrated that the clonal burden of SF3B1 mutation in myelodysplastic neoplasms informs classification and prognosis. Our findings support the notion that NPM1 mutation should be AML-defining regardless of blast percentage and highlight the adverse prognostic impact of the cumulative number of myelodysplasia-related mutations in NPM1-mutated AML. Finally, we provide evidence that integrating specific molecular signatures could improve the accuracy of oligomonocytic chronic myelomonocytic leukemia classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Using comprehensive clinical and molecular profiling, this study provides a data-driven approach for evaluating numerical thresholds of variant allele frequency or hematologic parameters (i.e., blast percentage and absolute monocyte count) included in current classification schemas across a spectrum of myeloid malignancies, enabling refinement of disease classification and prognostication.<\/jats:p>\n                    <jats:p>Watch the interview with Sanam Loghavi, MD, about this article: https:\/\/vimeo.com\/1115626649<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0047","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T13:55:09Z","timestamp":1751550909000},"page":"425-436","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-0624","authenticated-orcid":false,"given":"Curtis A.","family":"Lachowiez","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9479-5451","authenticated-orcid":false,"given":"Georgios","family":"Asimomitis","sequence":"additional","affiliation":[{"name":"2Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2057-7187","authenticated-orcid":false,"given":"Elsa","family":"Bernard","sequence":"additional","affiliation":[{"name":"3Computational Clinical Oncology Laboratory, Unit\u00e9 Mixte de Recherche 981, Gustave Roussy, Villejuif, France."},{"name":"4IHU PRISM (National Precision Medicine Center in Oncology), Gustave Roussy, Villejuif, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-720X","authenticated-orcid":false,"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[{"name":"2Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1595-9631","authenticated-orcid":false,"given":"Yanis","family":"Tazi","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0871","authenticated-orcid":false,"given":"Maria","family":"Creignou","sequence":"additional","affiliation":[{"name":"6Phase 1 unit, Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden."},{"name":"7Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6027-6388","authenticated-orcid":false,"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, University Clinic, D\u00fcsseldorf, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-2495","authenticated-orcid":false,"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, University Clinic, D\u00fcsseldorf, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2236-8852","authenticated-orcid":false,"given":"Amanda","family":"Gilkes","sequence":"additional","affiliation":[{"name":"9Cardiff University, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-8075","authenticated-orcid":false,"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[{"name":"9Cardiff University, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-5510","authenticated-orcid":false,"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Oncology, and Cancer Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt Universit\u00e4t zu Berlin, and Berlin Institute of Health, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-9862","authenticated-orcid":false,"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"11Department of Internal Medicine III, Ulm Univeristy Hospital, Ulm, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-1611","authenticated-orcid":false,"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"12Department of Molecular Medicine, University of Pavia, Pavia, Italy."},{"name":"13Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"additional","affiliation":[{"name":"14Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom."},{"name":"15Faculty of Medicine and Health, University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"14Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom."},{"name":"16Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-1419","authenticated-orcid":false,"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[{"name":"17The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-0251","authenticated-orcid":false,"given":"Deedra","family":"Nicolet","sequence":"additional","affiliation":[{"name":"17The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[{"name":"18Department of Leukemia, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"18Department of Leukemia, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"18Department of Leukemia, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"18Department of Leukemia, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"18Department of Leukemia, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"18Department of Leukemia, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-5176","authenticated-orcid":false,"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[{"name":"18Department of Leukemia, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-8155","authenticated-orcid":false,"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"16Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-8817","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"19Fondazione IRCCS Policlinico San Matteo & University of Pavia, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"11Department of Internal Medicine III, Ulm Univeristy Hospital, Ulm, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-161X","authenticated-orcid":false,"given":"Brian J.P.","family":"Huntly","sequence":"additional","affiliation":[{"name":"20Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-0697","authenticated-orcid":false,"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"21Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-3743","authenticated-orcid":false,"given":"Eva","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[{"name":"22Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-8983","authenticated-orcid":false,"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[{"name":"2Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"23Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2026011211264097800_bib1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011211264097800_bib2","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"2026011211264097800_bib3","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"2026011211264097800_bib4","first-page":"2454","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood J Am Soc Hematol"},{"key":"2026011211264097800_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026011211264097800_bib6","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun"},{"key":"2026011211264097800_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2026011211264097800_bib8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2026011211264097800_bib9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"11","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"2026011211264097800_bib10","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv"},{"key":"2026011211264097800_bib11","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/cncr.33745","article-title":"Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes","volume":"127","author":"Kanagal-Shamanna","year":"2021","journal-title":"Cancer"},{"key":"2026011211264097800_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"key":"2026011211264097800_bib13","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2009-08-240457","article-title":"Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)","volume":"115","author":"Falini","year":"2010","journal-title":"Blood"},{"key":"2026011211264097800_bib14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"key":"2026011211264097800_bib15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv"},{"key":"2026011211264097800_bib16","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","article-title":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia\u2013implications for the European LeukemiaNet risk classification","volume":"37","author":"Eckardt","year":"2023","journal-title":"Leukemia"},{"key":"2026011211264097800_bib17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/bloodadvances.2023011173","article-title":"Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML","volume":"8","author":"Chan","year":"2024","journal-title":"Blood Adv"},{"key":"2026011211264097800_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2026011211264097800_bib19","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1038\/s41375-022-01728-5","article-title":"SF3B1 mutated MDS: blast count, genetic co-abnormalities and their impact on classification and prognosis","volume":"36","author":"Huber","year":"2022","journal-title":"Leukemia"},{"key":"2026011211264097800_bib20","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"key":"2026011211264097800_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2026011211264097800_bib22","doi-asserted-by":"crossref","first-page":"e70060","DOI":"10.1002\/hem3.70060","article-title":"Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML","volume":"9","author":"Cocciardi","year":"2025","journal-title":"Hemasphere"},{"key":"2026011211264097800_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3\u2013internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council Report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026011211264097800_bib24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"key":"2026011211264097800_bib25","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","article-title":"Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax","volume":"5","author":"Lachowiez","year":"2021","journal-title":"Blood Adv"},{"key":"2026011211264097800_bib26","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"2026011211264097800_bib27","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"key":"2026011211264097800_bib28","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"2026011211264097800_bib29","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/bloodadvances.2022007359","article-title":"Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum","volume":"6","author":"Calvo","year":"2022","journal-title":"Blood Adv"},{"key":"2026011211264097800_bib30","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2016-12-753210","article-title":"Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis","volume":"129","author":"Talati","year":"2017","journal-title":"Blood"},{"key":"2026011211264097800_bib31","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"key":"2026011211264097800_bib32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc.2017.40","article-title":"Turning the tide in myelodysplastic\/myeloproliferative neoplasms","volume":"17","author":"Deininger","year":"2017","journal-title":"Nat Rev Cancer"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0047\/3628141\/bcd-25-0047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0047\/3639732\/bcd-25-0047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/5\/425\/3646147\/bcd-25-0047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/5\/425\/3646147\/bcd-25-0047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:26:51Z","timestamp":1768235211000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/5\/425\/764331\/Multimodal-and-Data-Driven-Assessment-of-Myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7,3]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0047","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.32728261","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728294","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728282","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728252","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728285","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728240","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728273","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728270","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728291","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728258","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728246","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728279","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728249","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728237","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728243","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728276","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728264","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728297","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728234","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728267","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728288","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32728255","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8545159","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}